iBio is a unique plant-based platform that offers a number of significant advantages over other systems:

• Ability to synthesize complex proteins at which other systems have failed
• Simplicity, scalability and flexibility
• Reduced capital investment
• Lower operating costs
• Surge capacity
• Rapid production times – gene sequence to factory-scale protein harvest
• Eliminates the need of bioreactors
• Ability to synthesize complex proteins at which other systems have failed
• Low risk of contamination by animal pathogens

iBio has a strong IP/technology portfolio and has been well established by more than nine years of applications development and $100 million in funding. Our current pipeline includes:

• Monoclonal antibodies
• Interferons & cytokines
• Enzymes for replacement therapy
• Plasma-derived proteins
• Growth factors
• Protease inhibitors
• Clotting factors
• Vaccines

iBioLaunch

The iBioLaunch™ platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins. The plants are easily and reliably scaled-up in low cost, controlled growth facilities to produce large amounts of recombinant protein in the plant biomass. The technology is highly flexible having the capability to produce both biotherapeutics and vaccines. Advantages of the whole plant approach include lower operating and capital expenses compared to protein production using engineered microbial or animal cells in bioreactors. The iBioLaunch platform offers significant advantages over earlier plant-based methods that rely on transgenic plants or plant cell cultures. These include the speed at which different proteins can be expressed and produced at commercial scale, which presents a significant commercial advantage, as well as public safety benefits when vaccines for pandemic diseases are required. Other advantages include scalability, no risks of contamination by animal pathogens, and the ability to express complex proteins at which other systems have failed.

For more information on iBioLaunch please Click Here.

Products

Our technology has been validated across a wide range of applications in both vaccines and biotherapeutics, and these products are available for license along with the technology to bring innovative medicines to patients.

Vaccines

The iBioLaunch expression platform has been used to manufacture vaccine candidates that represent a broad range of viral, bacterial, and parasitic threats to human health. The technology has been used to successfully produce vaccine components that could not be manufactured using bacterial, yeast, or animal cell expression systems, demonstrating a breadth of application that is unmatched. Each of these vaccines is available to be licensed from iBio along with the iBioLaunch manufacturing platform, providing a turnkey entry into vaccine development and manufacturing:

• Influenza vaccines
• Malaria
• Hookworm
• Yellow Fever
• Human papilloma virus
• Bacterial pathogens

Robert B. Kay, Executive Chairman

Mr. Kay is an accomplished business strategist and senior manager with extensive M&A, JV, and international licensing experience. Mr. Kay is a principal of Seaway Hotels, Inc., a hotel ownership and management group with more than 1200 employees. Mr. Kay was a founder and senior partner of the New York law firm of Kay Collyer & Boose LLP, with a particular focus on cross-border mergers and acquisitions and joint ventures. Previously, Mr. Kay served as a director for Genesys S.A. (West Corporation French subsidiary). He received his B.A. from Cornell University’s College of Arts & Sciences and his J.D. from New York University Law School.

Robert L. Erwin, President

Mr. Erwin previously led Large Scale Biology Corporation from its founding in 1988 through 2003, including a successful initial public offering in 2000, and continued as non-executive Chairman until 2006. Mr. Erwin recently served as Managing Director of Bio-Strategic Directors LLC providing consulting services to the life sciences industry. He served as Chairman of Icon Genetics AG from 1999 until its acquisition by a subsidiary of Bayer AG in 2006. He is currently Chairman of Novici Biotech, a private biotechnology company and a Director of Resolve Therapeutics LLC. Mr. Erwin’s non-profit work focuses on applying scientific advances to clinical medicine, especially in the field of oncology. He is co-founder and President of the Marti Nelson Cancer Foundation, and a member of the Cancer Policy Forum of the Institute of Medicine. Mr. Erwin received his B.S. degree with Honors in Zoology and an M.S. degree in Genetics from Louisiana State University.

Terence E. Ryan, PhD, Chief Scientific Officer

Dr. Ryan is a pharmaceutical and biotech research leader who is highly accomplished in recombinant protein expression, and also has a record of innovation in cell biology, proteomics, and systems biology.. His distinguished 20-year career includes working for such industry leaders as Wyeth (Pfizer) Research, GlaxoSmithKline, Celera Genomics, and Regeneron Pharmaceuticals. Dr. Ryan holds an MS and PhD in Microbiology from Rutgers University, and received his AB in Biology from Princeton University.

Douglas C. Hicks, Vice President, Business Development

Douglas Hicks is the Vice-President, Business Development for iBio, Inc. Mr. Hicks has over thirteen years of operational, financial, and administrative experience within both small and large businesses. He has primarily focused on business development, corporate planning, and strategy execution within the biotechnology, pharmaceutical, and private equity segments. Prior to joining iBio in 2010, Mr. Hicks was with Clearview Projects, Inc., a strategic advisory firm which provides business development, product alliance, and strategic advice to the pharmaceutical and biotechnology industry. Mr. Hicks joined Clearview when the firm was formed in 2001 and has held various roles of increased responsibility over the past 10 years, most recently as Executive Director of Business Development and Strategic Analysis. While at Clearview, he participated in over thirty-five strategic transactions across various therapeutic areas. Before joining Clearview, Mr. Hicks was a consultant at Bristol-Myers Squibb. Mr. Hicks received his MBA from The Pennsylvania State University, with a focus on finance and strategy.

Douglas Beck, Chief Financial Officer

Mr. Beck has extensive prior experience in public accounting including at both Andersen LLP and Eisner Amper LLP, and in corporate management as chief financial officer of two public companies, first an electronics company and then a biopharmaceutical company. In 2005, he was appointed CFO of Lev Pharmaceuticals, Inc. (Lev) where he was responsible for financial planning, financial reporting, accounting and tax matters. Mr. Beck worked with the executive team in the successful sale of Lev to ViroPharma, Incorporated. Mr. Beck is a graduate of Fairleigh Dickinson University where he received a Bachelor of Science degree in accounting. He serves on the SEC Practice Committee and the Chief Financial Officers Committee for the New York State Society of CPAs.

Wayne P. Fitzmaurice, Ph.D., Vice President, Intellectual Property

Dr. Fitzmaurice has extensive experience in plant biotechnology research, and is a USPTO certified Patent Agent.  He led research teams at Biosource Technologies (later Large Scale Biology Corp.) for 15 years from 1992 to 2007 ultimately holding the position of Senior Director of Plant Biology and Pharmaceutical Development.  He is a founding partner of Novici Biotech, and functions as their Senior Director of Intellectual Property.  With Novici he is on key patents as both an inventor and a prosecuting patent agent.  He also acted as an independent consultant in biotechnology intellectual property for several corporations.  Dr. Fitzmaurice received a Ph.D. in Biochemistry from The Johns Hopkins University, and did postdoctoral research at the University of Wisconsin-Madison and North Carolina State University.

For stock information please Click Here.